CDKN2A and cancer: Current cancer chemotherapy uses etoposide to induce DNA double-strand breaks for cell killing, which can cause fluctuations in stemness promoters like OCT4A, SOX-2, or NANOG in relation to senescence promoters p21Cip1, p27, or p16ink4A, and mitigate anti-cancer therapy.